News Tysabri failure in stroke a setback for Biogen Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.
News Roche's MS drug Ocrevus priced in line with Novartis rival i... Drug likely to cost just under £10,000 per six-monthly injection.
News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Bill Gates enters dementia research with $50m donation Fund is challenging prevailing 'amyloid hypothesis'
News Biogen sees Spinraza slow down in Q3, bullish on Alzheimer's... Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a rapid slowdown for its new rare disease drug Spinraza.
News Amgen's big reveal of obesity data falls a little flat Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
